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Heart failure (HF) with preserved ejection fraction (HFpEF) is a
clinical syndrome of HF symptoms associated with impaired diastolic
function. Although it represents 50% of patients with HF, the
mechanisms of disease are poorly understood, and therapies are
generally ineffective in reducing HF progression. Animal models of
HFpEF not due to pressure or volume overload are lacking, therefore
limiting in-depth understanding of the pathophysiological mecha-
nisms and the development of novel therapies. We hypothesize that a
continuous infusion of low-dose angiotensin II (ATII) is sufficient to
induce left ventricular (LV) diastolic dysfunction and HFpEF, without
increasing blood pressure or inducing LV hypertrophy or dilatation.
Osmotic pumps were implanted subcutaneously in 8-wk-old male
mice assigned to the ATII (0.2 mg·kg1·day1) or volume-matched
vehicle (N  8/group) for 4 wk. We measured systolic and diastolic
arterial blood pressures through a tail-cuff transducer, LV dimensions
and ejection fraction through echocardiography, and LV relaxation
through pulsed-wave Doppler and LV catheterization. Myocardial
fibrosis and cardiomyocyte cross-sectional area were measured. ATII
infusion had no effects on systemic arterial blood pressure. ATII
induced significant impairment in LV diastolic function, as measured
by an increase (worsening) in LV isovolumetric relaxation time,
myocardial performance index, isovolumetric relaxation time con-
stant, and LV end-diastolic pressure without altering LV dimensions,
mass, or ejection fraction. Chronic infusion of low-dose ATII recapit-
ulates the HFpEF phenotype in the mouse, without increasing sys-
temic arterial blood pressure. This mouse model may provide insight
into the mechanisms of HFpEF.
heart failure with preserved ejection fraction; diastolic dysfunction;
animal model; angiotensin II; end-diastolic pressure; isovolumetric
relaxation time
NEW & NOTEWORTHY
Chronic infusion of low-dose angiotensin II in the mouse
induces diastolic dysfunction and HFpEF in the absence of
pressure overload, LV systolic dysfunction, LV dilatation or
hypertrophy, and metabolic abnormalities. This model may be
considered a novel tool for mechanistic preclinical studies in
HFpEF with translational potential.
HEART FAILURE (HF) WITH PRESERVED ejection fraction (HFpEF) is
a clinical syndrome of symptoms of HF, such as breathlessness
and exercise intolerance, associated with impaired left ventric-
ular (LV) diastolic function in the presence of a normal LV
ejection fraction (LVEF 50%) (2). HFpEF carries significant
morbidity and mortality burdens, and the prevalence of the
disease has increased over the past 30 yr (2, 17). To date, the
mechanisms underlying diastolic dysfunction and the progres-
sion of HFpEF are poorly understood. The pathophysiology
involves impaired LV relaxation and contractile reserve, in-
creased LV stiffness, as well as abnormal renal sodium han-
dling, arterial stiffness, and aberrant ventriculo-arterial cou-
pling (2).
The limited availability of animal models of HFpEF has
potentially represented a major limitation in conducting mech-
anistic studies in the field (11). The animal models of HFpEF
have hitherto involved mostly studies of increased afterload
and LV hypertrophy (i.e., aortic banding or systemic arterial
hypertension), models of increased preload (i.e., aorto-caval
fistulas), or models of altered metabolism (i.e., obesity, diabe-
tes, hyperlipidemia), making it difficult to distinguish between
the intrinsic mechanism(s) of diastolic dysfunction vs. the
mechanism(s) causing dysfunction (11). Moreover, aortic
banding and aorto-caval fistulas do not reflect clinically exist-
ing conditions, and the majority of patients with HFpEF
continue to have HF symptoms, even when they have con-
trolled blood pressure (BP). In fact, HFpEF patients have LV
hypertrophy in 50% of cases and often show no evidence of
increased preload or LV dilatation, thus making the value of
the current preclinical models questionable (1, 2, 11).
Angiotensin II (ATII) occupies a central role in homeostasis,
hypertension, and HF, regulating afterload, preload, cardiac
hypertrophy, and fibrosis (4). Chronic infusion of ATII has
been used as a model of chronic hypertension, while low-dose
infusion of ATII affects the cardiovascular system without
inducing systemic arterial hypertension (4).
We hypothesized that low-dose ATII would reproduce the
cardiac phenotype of HFpEF in the mouse in the absence of
elevations in systemic arterial BP or LV hypertrophy, and thus
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serve as a preclinical model of HFpEF free of confounding
factors.
METHODS
Ethical aspects. The experiments were conducted under the guide-
lines of the “Guide for the Care and Use of Laboratory Animals”,
published by the National Institutes of Health (revised 2011). The
study protocol was approved by the Virginia Commonwealth Institu-
tional Animal Care and Use Committee.
Experimental model. Eight-week-old outbred male CD1 mice were
supplied by Harlan (Indianapolis, IN). Mice were sedated with pen-
tobarbital (50–70 mg/kg), and osmotic mini-pumps (DURECT, Cu-
pertino, CA) were sterilely implanted in the intrascapular space to
allow subcutaneous infusion of low-dose ATII (0.2 mg·kg1·day1)
or vehicle sterile water (at the same flow rate), for 28 days. Mice were
randomly assigned to different groups: sham-operated mice (no im-
plantation of any pump; N  8); mice implanted with an infusion
pump that infused vehicle for 28 days (N  8); and mice implanted
with an infusion pump with ATII for 28 days (N  8). The infusion of
vehicle had no significant effects on any of the measured parameters
and was indistinguishable from the sham-operated mice, and, there-
fore, throughout the rest of the paper, only data of vehicle are shown
compared with ATII pump, while data on the sham-operated mice are
not presented.
Noninvasive arterial BP measurement. We measured systolic and
diastolic arterial BP at baseline and at 28 days using a noninvasive
tail-cuff BP analyzer (CODA System, Kent Scientific, Torrington,
CT). Ten cycle measurements were collected through a dedicated
software, and the mean was calculated for both the systolic and the
diastolic BP (7).
Echocardiography. All mice underwent transthoracic echocardiog-
raphy at baseline (before surgery) and at 28 days, under light anes-
thesia (50 mg/kg pentobarbital sodium). Echocardiography was per-
formed with the Vevo770 imaging system (VisualSonics, Toronto,
Ontario, Canada) and a 30-MHz probe (3). The heart was visualized
in B-mode from parasternal short-axis and apical views. We measured
the LV end-diastolic diameter, LV end-systolic diameter, LV anterior
wall diastolic thickness, and LV posterior wall diastolic thickness at
M-mode, as previously described and according to the American
Society of Echocardiography recommendations (3). LV fractional
shortening, LVEF, and LV mass were calculated from the measure-
ments of wall thickness and chamber diameters. Right ventricular
(RV) systolic function was estimated using M-mode and measuring
the tricuspidal annular plane systolic excursion (24). The transmitral
LV outflow tract Doppler spectra (E, A, ET) was recorded from an
apical four-chamber view, and the myocardial performance index
(MPI) was calculated as the ratio of isovolumetric contraction time
and isovolumetric relaxation time (IRT) divided by the ejection time
(21). Tissue Doppler was used to measure the lateral E= spectra, and
calculate the E-to-E= ratio (E/E=). Two-dimensional video loops were
reviewed for abnormalities in the pericardial structure (effusion or
thickening), RV dilatation, or interventricular dependence. The inves-
tigators performing and reading the echocardiograms were blinded to
the treatment allocation.
LV catheterization. Mice were anesthetized (70 mg/kg pentobarbi-
tal sodium), and a pressure probe catheter (AD Instruments, Colorado
Springs, CO) was retrogradely inserted in the LV from the right
carotid artery. LV end-diastolic pressures (LVEDP), and the pressure-
volume loops were recorded and measured using LabChart Pro 5 (AD
Instruments). The end-diastolic pressure-volume relationship (ED-
PVR) and end-systolic pressure-volume relationship (ESPVR) were
calculated by pressure-volume measurements by concomitant Millar
catheter and transthoracic echocardiography (29). Changes in preload
were studied in a closed chest system, applying a resistance to preload
by inflating the lungs artificially using a standard tidal volume (7.5
m/g body wt) and rate (300 breaths/min). To determine changes in
preload, the ventilator was turned off, allowing for a progressive
increase of venous return and recording several consecutive beats. The
EDVPR and ESPVR were then calculated according to the changes in
pressure-volume loops by interpolating the points of end-diastolic
pressure and end-systolic pressure with and without preload. The IRT
constant, , was measured using the formula P  P0et/, where P
represents the diastolic pressure, P0 is the pressure at the moment of
maximum dP/dT, and t is the IRT.
Sample collection. Immediately following LV catheterization,
hearts were rapidly excised and placed in 10% formalin and fixed for
a minimum of 48 h and then embedded in paraffin. The lungs and the
pericardium were inspected for gross anatomical abnormalities. Em-
bedded heart tissues were sectioned into 5-m slides and stained with
Masson’s trichrome (Sigma-Aldrich) to detect collagen fibers. The
area of myocardial fibrosis was measured as percentage of collagen
area on total myocardial tissue area. The cross-sectional area (CSA) of
cardiomyocytes was measured to determine cardiomyocyte hypertro-
phy. Computer morphometry was performed using Image J software.
Statistical analysis. All statistical analyses were performed using
SPSS 21.0 package for Windows (Chicago, IL). Continuous variables
are expressed as mean and SE, and one-way ANOVA to compare
between three or more groups at any individual time point, followed
by Bonferroni-corrected T-test for unpaired data was used. For inter-
val changes over time, comparing ATII and vehicle infusion, an
ANOVA for repeated measures was used, assessing the time 	 group
interaction. P values  0.05 were considered statistically significant.
RESULTS
Procedural data. Sixteen mice underwent infusion pump
implantation without any acute or late mortality (100% sur-
vival). Morphometric data are reported in Table 1.
Systemic arterial BP measurement. Systolic and diastolic
arterial BP values, measured noninvasively with a tail cuff,
were within the normal range before implantation of the pump
and remained unchanged after 28-day infusion of ATII (N  4,
all P  0.81, Fig. 1).
Echocardiography. LV mass, LV end-diastolic diameter,
LVEF, and tricuspidal annular plane systolic excursion values
were unchanged between baseline and after 28 days of infusion
of ATII or vehicle (all P  0.22, Fig. 2). In the ATII group, the
RV and the pericardium did not show abnormalities.
Representative images of the pulsed wave Doppler spectra
are shown in Fig. 3. Table 2 reports Doppler data for each
group. ATII infusion induced a significant impairment in LV
diastolic function, as measured by a significant increase of the
IRT and of the MPI vs. baseline values (P  0.018 and P 
0.001, respectively), whereas vehicle infusion had no signifi-
cant effects on IRT or MPI (all P  0.23) (Fig. 3). No changes
in E/E= were observed between the groups.
LVEDP. Representative images of the pressure changes over
time are reported in Fig. 4. ATII-treated mice showed signifi-
cantly increased LVEDP, , and EDPVR compared with vehi-
cle-treated mice (P  0.002, P  0.001, and P  0.040,
Table 1. Morphological parameters
Group BW, g LVM, mg LVEDD, mm LVESD, mm
ATII 38.4 
 0.8 108
 7 3.96 
 0.10 2.58
 0.13
Vehicle 39.0 
 0.9 96
 5 4.19
 0.06 2.63
 0.13
Values are group means 
 SE; N  8 animals/group. ATII, angiotensin II;
BW, body weight; LVM, left ventricular mass; LVEDD, left ventricular
end-diastolic diameter; LVESD, left ventricular end systolic diameter. All P
0.15.
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respectively, Fig. 4), reflecting increased LV elastance. The
ESPVR was unchanged, reflecting similar systolic perfor-
mance between the control vehicle and the ATII-treated mice.
Cardiomyocyte hypertrophy and interstitial myocardial
fibrosis. Histological analysis revealed that ATII led to a
significantly increased cardiomyocyte CSA vs. vehicle (P 
0.01, Fig. 5), reflecting cardiomyocyte hypertrophy. ATII treat-
ment also led to increased interstitial myocardial fibrosis com-
pared with the vehicle-treated group (P  0.036, Fig. 5). The
associations between the cardiomyocyte CSA or the interstitial
fibrosis and IRT, MPI, and LVEDP are shown in Fig. 6. We
found no statistically significant correlation between cardio-
myocytes hypertrophy and fibrosis (R  0.38, P  0.28), or
between these parameters with IRT, MPI, and LVEDP within
the individual animals (Fig. 5).
DISCUSSION
Chronic infusion of low-dose ATII recapitulates the pheno-
type of HFpEF in the mouse, independent of systemic arterial
hypertension and/or LV hypertrophy. HFpEF is a clinical
syndrome of breathlessness, fatigue, and exercise intolerance,
despite preserved LV systolic function (LVEF 50%), and
direct or indirect evidence of diastolic dysfunction and/or
elevated LV filling pressures, in the absence of other structural
or functional abnormalities that may explain such symptoms
(2, 19). HFpEF is a clinically heterogeneous syndrome, and,
unlike other cardiac diseases, the incidence of HFpEF is
increasing (2). Therapeutic strategies that benefit patients with
HF with reduced ejection fraction (EF) (or systolic HF) have
proven to be marginally effective or ineffective in patients with
HFpEF (2). Despite the disease burden of HFpEF and associ-
Fig. 1. Systemic arterial blood pressure. The figure shows the lack of effect of
a low dose of angiotensin II (ATII) infusion on systemic arterial blood pressure.
Systolic and diastolic blood pressure values measured with a tail cuff at
baseline and after 28 days of infusion of ATII are shown. Triangles, mean
arterial systolic blood pressure; squares, mean arterial diastolic blood pressure.
Values are group means 
 SE; N  4 animals/time point.
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Fig. 2. Echocardiographic measurement of left ventricular (LV) dimensions
and systolic function. The figure shows lack of effect of a low dose of ATII
infusion on LV end-diastolic diameter (LVEDD, expressed in mm), the LV
mass (expressed in mg), LV ejection fraction (LVEF, expressed as percentage),
and tricuspid annulus plane systolic excursion (TAPSE, expressed in mm).
Values are means 
 SE; N  8 animals/group.
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Fig. 3. Pulse-wave Doppler spectra. A and B: representative images of
pulse-wave Doppler recordings at baseline before ATII infusion and after 28
days, respectively. The isovolumetric contraction time (ICT), ejection time
(ET), and isovolumetric relaxation time (IRT) are indicated. Myocardial
performance index (MPI; C) and IRT (expressed in ms; D) of the mice infused
with ATII or the control vehicle at baseline and after 28 days of infusion are
shown. Values are means 
 SE; N  8 animals/group. *P  0.001. &P 
0.018.
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ated morbidity and mortality, the pathophysiology remains
unclear (2). Understanding the mechanisms involved in the
progression of HFpEF is further complicated by the many
comorbidities and risk factors affecting HFpEF patients, in-
cluding age, obesity, hypertension, and diabetes. Therefore,
there is a need for additional and more accurate preclinical
models to understand the pathogenesis of HFpEF and poten-
tially develop targeted therapies.
In this regard, an animal model of HFpEF that explores
diastolic dysfunction independent of LV hypertrophy and/or
pressure overload and of metabolic changes is lacking, al-
though several animal models have been proposed to study
HFpEF (11). The mouse model of transaortic constriction is a
pressure-overload model where a band is placed around the
aorta, and, as the mouse grows, the band becomes obstructive
by preventing sufficient enlargement of the aortic CSA, thus
increasing afterload (5, 15, 23). This model is subject to
procedural variability based on the size of the banding, the age
of mice at time of surgery, and the length of follow up, but
most importantly the diastolic dysfunction is secondary to
pressure overload and dependent on the severity and rapidity of
onset of the constriction. As such, this model represents more
closely a model of progressive aortic valve stenosis rather than
a model of HFpEF. This model also develops decompensated
eccentric LV hypertrophy associated with LV systolic dysfunc-
tion, which is an uncommon feature in HFpEF, as the evolution
to HF with reduced EF is uncommon in patients with HFpEF
(2). Of note, in some experimental settings, the banding was
applied to induce a relatively rapid pressure overload (18).
However, the clinical translational value of these models is
difficult to understand, since, with the exception of acute
prosthetic aortic valve thrombosis, or perhaps an acute hyper-
tensive crisis in a patient without hypertension, a clinical
scenario of acutely increased afterload is not observed.
Other commonly used models of diastolic dysfunction are
related to systemic hypertension in the rat (16). The spontane-
ous hypertensive rat and the salt-sensitive rat models are
models of cardiac dysfunction in the setting of large increases
Table 2. Waive Doppler and tissue Doppler parameters
Group E A E/A S= E= A= E/E=
ATII 703 
 45 266 
 35 2.52 
 0.27 15.9 
 0.7 15.0 
 1.4 11.6 
 0.8 47 
 5
Vehicle 668
 13 300 
 51 2.42 
 0.39 15.5 
 0.6 12.4 
 1.2 9.3 
 1.4 57 
 5
Values are group mean 
 SE; N  8 animals/group. All P  0.13.
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Fig. 4. LV catheterization. A and B: representative images
of pressure-volume loop recordings of vehicle or ATII
infusion for 28 days, respectively. The LV end-diastolic
pressure (LVEDP) values were used to calculate the
end-diastolic pressure-volume relationship (EDPVR)
originated by pressure-volume loops with preload imped-
iment by positive pressure ventilation and on spontaneous
respiration. C: the LVDEP (expressed in mmHg) mea-
sured after 28 days of ATII or control vehicle infusion. D:
the EDPVR slope values (expressed as mmHg/l) of ATII
or control vehicle infusion. E: the ESPVR slope values
(expressed as mmHg/l) of ATII or control vehicle
infusion. F: the IRT time constant . Values are group
means
 SE; N 6–8 animals/group. *P 0.002. &P
0.04. #P  0.001.
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in systemic arterial BP (27). These models are useful in
studying hypertensive cardiomyopathy, which also evolves
through concentric LV hypertrophy with preserved EF to
eccentric LV hypertrophy with reduced EF (11). While many
patients with HFpEF have arterial hypertension, less than
one-half have LV hypertrophy, and eccentric LV hypertrophy
with reduced EF is not a common feature of HFpEF (2).
The rodent model of aorto-caval fistula is a model of volume
overload characterized by biventricular hypertrophy, LV en-
largement, and increased systolic and diastolic pressure (1).
This model is used to study congestive HF, and, therefore, the
prominent systolic nature of ventricular dysfunction represents
a limitation of the use of this model to study diastolic dysfunc-
tion (26, 28).
The db/db leptin receptor-deficient morbidly obese mouse
has been used as a model of HFpEF; however, diastolic
dysfunction is associated with morbid obesity and severe
hyperglycemia secondary to diabetes (22). The db/db model
has an inherent value in exploring the contribution of obesity
and metabolic syndrome, often seen in patients with HFpEF,
but may not be representative of all patients with HFpEF. The
ZSF1 obese rat model is a model of metabolic dysfunction in
which HFpEF is associated with obesity and diabetes (9). The
rat develops HF in association with hyperglycemia and insulin
resistance, and, therefore, while it may represent a good model
for HFpEF with metabolic alterations, it is unlikely to be
representative of all patients with HFpEF. Genetic modifica-
tions of titin and cardiac myosin binding protein C have also
been proposed as models of HFpEF (12, 25). These genetic
models allow for the intrinsic changes to develop progressively
as the mouse grows and ages, but do not reflect the clinical
HFpEF syndrome.
Unlike other models of ATII infusion at higher doses, which
induce significant systemic hypertension, we used a subpressor
dose of ATII that recapitulates the enhanced activation of the
renin-angiotensin-aldosterone system (RAAS) in patients with
HFpEF, devoid of systemic arterial hypertension (17, 28). The
proposed model, therefore, differs from prior models by the
Fig. 5. Measurement of cardiomyocyte hypertrophy and quantification of the interstitial fibrosis. A and B: Masson’s Trichrome stain on heart sections were used
to visualize the cross-sectional areas of cardiomyocytes (	20 magnification) of mice infused with control vehicle or ATII, respectively. C and D: areas of
magnification of A and B, respectively. E: quantification of the cardiomyocyte cross-sectional areas of the control vehicle and ATII infused mice. F and G:
representative pictures of Masson’s Trichrome staining to quantify the fibrosis in tissue sections of hearts of mice infused with control vehicle or ATII,
respectively (	20 magnification). H and I: areas of magnification of F and G, respectively. J: quantification of the interstitial fibrosis reported as percentage (%)
of the area of fibrotic tissue on the total area. Values are group means 
 SE; N  8 animals/group. *P  0.05.
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absence of increased afterload, hypertrophy, dilatation, or met-
abolic abnormalities, and as such it is likely to provide infor-
mation that is not available from the others, yet it is comple-
mentary to the already available models. This model shows
that, in the mouse, ATII signaling is sufficient to induce
diastolic dysfunction and HFpEF. This may appear at odds
with clinical trials, failing to clearly show significant benefits
in survival with blockers of the RAAS (2). It should be
considered, however, that RAAS blockers in HFpEF have been
mostly tested on top of other vasodilators and allowed for
crossover to open-label treatments, thus biasing toward the null
hypothesis (8, 13). Moreover, failure of RAAS blocker to
improve outcomes in HFpEF should not be viewed as proof of
a pathogenic role of ATII in HFpEF, as it may simply reflect
the inability of RAAS blockers to reverse the disease process
once fully established.
We describe that infusion of subpressor doses of ATII in the
mouse leads to increased IRT, , MPI, EDPVR, and LVEDP,
indicative of impaired myocardial relaxation, increased elas-
tance, wall stress, and diastolic dysfunction. The inability to
assess for symptoms of HF is an obvious limitation to any
animal study. Nevertheless, the increase in LVEDP is consid-
ered a reliable sign of HF. The increase in IRT and  and the
upward shift in EDPVR in absence of changes in the pericar-
dium or RV suggest that the LVEDP is indeed due to abnormal
LV relaxation and/or elastance. We did not find a change in
E/E= in this study: while this appears to be at odds with the
reported finding of increased E/E= in patients with HFpEF, it
should be considered that elevation in the E/E= may only occur
when LVEDP is markedly increase (i.e., 20 mmHg in pa-
tients with HFpEF) and, therefore, be a less sensitive marker of
HFpEF (14). We measured changes in LVEDP and EDPVR in
a closed chest/abdomen model, representing a potential way to
reduce confounders related to surgery, bleeding, pain, and
changes in temperature in the chest. Pentobarbital sodium has
become the preferred sedative in our experiments, as it does
not interfere with physiological or pharmacological precondi-
tioning, and, although it likely reduced heart rate, contractility,
and lusitropy in all groups, we expect the effects to be equal in
all groups and thus not interfere with the comparisons between
groups.
The histological analysis revealed also mild, but significant,
increase in cardiomyocyte size (hypertrophy) and interstitial
fibrosis, indicative of increased cardiac elastance. These
changes developed in the absence of hypertension, systolic
dysfunction, or LV remodeling. This model of chronic low-
dose ATII infusion may, therefore, be a novel and useful tool to
provide in-depth mechanistic insight for understanding the
development and contribution of diastolic dysfunction in HF-
pEF, independent of genetic modifications, metabolic abnor-
malities, or pressure and volume overload.
This model, however, is not without limitations. First, we
only studied young adult male CD1 mice. In the future,
additional studies should initiate low-dose ATII infusion in
aging mice to understand how the disease progression may be
altered with age. HFpEF is more prevalent in women; there-
fore, it will be crucial to examine this model in female mice, at
various stages of their life (i.e., pre- and post-ovarian senes-
Fig. 6. Relationship between hypertrophy and fibrosis with diastolic dysfunction. The graphs report the distribution of the values of fibrosis (top) or
cross-sectional area (bottom) in relation to the MPI, end-diastolic pressure (EDP), and IRT in the control vehicle group (open circles) and in the low-dose ATII
group (solid squares). Differences between groups are statistically significant. No significant correlations were observed in the distribution of the values. Values
are group means 
 SE.
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cence or ovariectomized mice). The characteristic hypertrophic
response in females may be protective in some instances but
deleterious in others, such as in HFpEF (20). The infusion may
also be extended to determine whether disease severity in-
creases with a longer infusion period, and to see if mice will
eventually develop systemic arterial hypertension, LV hyper-
trophy, and/or LV systolic dysfunction. The mechanisms by
which ATII induces diastolic dysfunction in this HFpEF model
are also not explored in this study. Impaired relaxation may be
a dynamic effect on calcium handling, or dependent on the
structural changes seen in interstitial fibrosis and cardiomyo-
cyte hypertrophy (10). An additional limitation is the lack of
data on isolated cardiomyocyte stiffness, shown to be abnormal
in HFpEF (6). We also did not measure changes in titin isoform
expression or phosphorylation status, which appear to regulate
the cardiomyocyte stiffness (9). The effects of ATII on cardi-
omyocyte stiffness and titin will require further focused inves-
tigations.
In conclusion, a 28-day infusion of subpressor dose of ATII
recapitulates the HFpEF features of impaired LV relaxation
and increased LV elastance in the absence of pressure over-
load, LV systolic dysfunction, LV dilatation or hypertrophy,
and metabolic abnormalities and may, therefore, be considered
as a novel tool for mechanistic preclinical studies in HFpEF
with immense translational potential.
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